Myriad Genetics, Inc.

NasdaqGS:MYGN Stock Report

Market Cap: US$1.2b

Myriad Genetics Future Growth

Future criteria checks 0/6

Myriad Genetics is forecast to grow earnings and revenue by 56.9% and 7% per annum respectively. EPS is expected to grow by 57.9% per annum. Return on equity is forecast to be 3.9% in 3 years.

Key information

56.9%

Earnings growth rate

57.9%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate7.0%
Future return on equity3.9%
Analyst coverage

Good

Last updated13 Dec 2024

Recent future growth updates

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Recent updates

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02
Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02
Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Sep 20
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Aug 30
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

Jul 17
Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Jun 05
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18
Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Aug 07
Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Apr 13
Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Earnings and Revenue Growth Forecasts

NasdaqGS:MYGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026966-12244812
12/31/2025882-7293315
12/31/2024841-1063615
9/30/2024824-116-107-70N/A
6/30/2024802-155-141-93N/A
3/31/2024774-235-155-96N/A
12/31/2023753-263-184-111N/A
9/30/2023734-274-138-63N/A
6/30/2023699-248-119-44N/A
3/31/2023695-146-155-93N/A
12/31/2022678-112-152-106N/A
9/30/2022661-77-143-108N/A
6/30/2022672-18-164-145N/A
3/31/2022682-8-117-100N/A
12/31/2021691-27119N/A
9/30/2021684-57-714N/A
6/30/2021662-97-26-6N/A
3/31/2021566-1481128N/A
12/31/2020557-224-40-27N/A
9/30/2020598-194-25-14N/A
6/30/2020639-1995161N/A
3/31/2020761-1485362N/A
12/31/2019813-264352N/A
9/30/2019835-158392N/A
6/30/201985157584N/A
3/31/20198302391100N/A
12/31/20187962696105N/A
9/30/20187675492100N/A
6/30/2018744133N/A116N/A
3/31/2018749130N/A105N/A
12/31/2017763126N/A134N/A
9/30/2017771101N/A133N/A
6/30/201772917N/A106N/A
3/31/201775732N/A108N/A
12/31/201675163N/A113N/A
9/30/201674894N/A134N/A
6/30/2016741117N/A166N/A
3/31/2016757121N/A179N/A
12/31/2015747108N/A163N/A
9/30/201573895N/A163N/A
6/30/201572380N/A141N/A
3/31/201572295N/A130N/A
12/31/2014725110N/A112N/A
9/30/2014745137N/A107N/A
6/30/2014778176N/A190N/A
3/31/2014764187N/A212N/A
12/31/2013737188N/A238N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MYGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MYGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MYGN's revenue (7% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: MYGN's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (3.9%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Myriad Genetics, Inc. is covered by 43 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack MeehanBarclays
Derek TallerBenchmark Company
Michael RyskinBofA Global Research